CLINICAL_TRIALS
trial_result
· 2018-11-29
Clinical Trial Update: Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study [Phase 3]
Summary
Phase 3 clinical trial EVOLVE-1 evaluating galcanezumab for prevention of episodic migraine has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2018-11-29